Small business owners are struggling to keep up with the rising cost of healthcare. Nearly a third have recently stopped ...

Hospitals are suing to block a Trump administration pilot that will allow drugmakers to issue post-sale rebates instead of upfront discounts on medications in the 340B drug discount program, arguing ...

Trump Puts Drug Pricing Program Fraudsters on Notice ...

Minnesota's 340B drug discount program faces scrutiny as small clinics struggle and large hospitals profit, sparking ...

As regulatory scrutiny increases and manufacturer restrictions continue to evolve, Halo 340B provides an intelligent safety net that transforms 340B management from a high-risk administrative burden ...

Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans. The lawsuits reflect rising tensions among drugmakers, ...

Congress should restore the 340B program to its original purpose, and New York lawmakers should do what they can not to make ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

On December 29, 2025—just three days before the 340B Rebate Model Pilot Program (the Rebate Program) was set to begin—the U.S. District Court for the District of Maine issued an order granting a ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...

The 340B drug plan language that was recently added into Senate Bill 494 risks increasing costs for the very patients it ...